Orchid Pharma share news, announcements and annual reports
NSE: ORCHPHARMABSE: 524372Pharmaceuticals & BiotechnologySmall Cap
Orchid Pharma Limited · Formerly Orchid Chemicals & Pharmaceuticals · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1993 on BSE, Jul 2007 on NSE
Last close ₹847.30up ₹10.85 (1.30%)BSE ₹846.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹836.45.
2 Nov: open ₹839.20, high ₹861.15, low ₹821.00
52-week range of traded prices to 2 Nov 2026
₹480.00Low, 30 Mar 2026₹1,143.50High, 22 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,074 Cr919th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 0.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.19
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,09,48449.1% delivered
Orchid Pharma share news and announcements
856 announcements, routine notices left out, newest first. Page 14 of 18.
Nov 2011
2 Nov · Disclosure
Compensation Committee of the Board at its meeting held on November 01, 2011, has approved the following : (1) The issue of 42,700 stock options to the employees of the Company under Orchid ESOP - Senior Management 2011 Scheme. The said stock options are to be issued at par and are convertible into equity shares of Rs. 10/- each; (2) The issue of 3,00,000 stock options to the Directors of the Company under Orchid ESOP - Directors 2011 Scheme. These options are convertible into equity shares of Rs. 10/- each at a price of Rs. 166.15 per share. Further, the Compensation Committee of the Board and the Board of Directors at their meetings held on November 01, 2011 have approved the repricing of 8,64,500 options granted to employees on October 28, 2010 under Orchid ESOP 2010 Scheme, from Rs. 329.55 to Rs. 166.15 per share, subject to the shareholder's approval and other consents as may be required.1 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 41222.25 lacs for quarter ending on 30-SEP-2011 against Rs. 36832.34 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 2343.2 lacs for the quarter ending on 30-SEP-2011 against Rs. 2401.49 lacs for the quarter ending on 30-SEP-2010.
Oct 2011
20 Oct · Board meeting
To take on record the Unaudited Financial Results of Orchid for period from July 01, 2011 to September 30, 2011.
Sep 2011
26 Sep · Updates
There was a fire that broke out in a portion of the New Drug Discovery Laboratories located in the Company's research subsidiary Orchid Research Laboratories Limited, Sholinganallur, Chennai. The fire was brought under control by the Tamil Nadu Fire Services squad assisted by the Orchid safety team. There was damage to office and laboratory equipment, furniture and building interiors. However, there were no injuries to anyone.
Aug 2011
Jul 2011
29 Jul · Retirement of Director
Dr. M. R. Girinath and Dr. I. Seetharam Naidu, who were Directors on the Board of Orchid were due to retire by rotation at the Annual General Meeting held on July 29, 2011. Both the directors retired from their directorship with effect from the close of the AGM, as they opted not to get re-elected.29 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 37376.02 lacs for quarter ending on 30-JUN-2011 against Rs. 30350 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 1554.25 lacs for the quarter ending on 30-JUN-2011 against Rs. 2161.48 lacs for the quarter ending on 30-JUN-2010.29 Jul · Results
18 Jul · Board meeting
To take on record the unaudited financial results of the Company for the period from April 01, 2011 to June 30, 2011.11 Jul · Updates
Orchid's Cephalosporin API manufacturing facility located in Alathur (Chennai) was issued a Closure Notice by the Tamilnadu Pollution Control Board (TNPCB) citing some non-compliance with regard to the disposal of solid waste. The Company is in active dialogue with the TNPCB officials and is confident of resolving the issues and bringing the plant to a fully operational stage at the earliest.
Jun 2011
30 Jun · Meeting
20 Jun · Meeting
May 2011
24 May · Management
Mr. Bala V Balachandran has been inducted into the Board of Orchid as Additional Director with effect from May 18, 2011. The appointment has been approved by the Board at its meeting held on May 18, 2011.18 May · Dividend
Dividend on Equity shares, if approved by the Members at the ensuing Annual General Meeting, will be paid / dispatched between August 16, 2011 and August 18, 2011.18 May · Dividend
Board of Directors of the Company at its meeting held on May 18, 2011 has recommended a dividend of Rs.3/- per share on the equity share of Rs.10/- each.18 May · Results
Consolidated Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 171698.61 lacs for year ending on 31-MAR-2011 against Rs. 129872.31 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 15618.72 lacs for the year ending on 31-MAR-2011 against Rs. 33925.38 lacs for the year ending on 31-MAR-2010.18 May · Results
Standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 159467.88 lacs for year ending on 31-MAR-2011 against Rs. 120518.59 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 15948.36 lacs for the year ending on 31-MAR-2011 against Rs. 33133.96 lacs for the year ending on 31-MAR-2010.4 May · Board meeting
To :- (1) Approve the audited financial results of the Company for the financial year ended March 31, 2011; (2) Consider recommendation of dividend on equity capital for the financial year ended March 31, 2011.4 May · Results
Company will be publishing the audited financial results for the year ended March 31, 2011 within a period of 60 days, i.e., on or before May 30, 2011.
Jan 2011
19 Jan · Management
Mr. R. Sankaran and Mr. Bharat Shah have been inducted into the Board of Orchid as Additional Directors with effect from January 19, 2011. Their appointments have been approved by the Board at its meeting held on January 19, 2011.19 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 42714.76 lacs for quarter ending on 31-DEC-2010 against Rs. 30883.77 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 5256.61 lacs for the quarter ending on 31-DEC-2010 against Rs. (1685.96) lacs for the quarter ending on 31-DEC-2009.7 Jan · Board meeting
To take on record the unaudited financial results of Orchid for the period from October 1,2010 to December 31,2010.
Nov 2010
Oct 2010
28 Oct · Management
Shri R. Narayanan, Chairman has resigned on October 28, 2010 from the Board of Orchid, given his health condition and age. Subsequent to his resignation, Shri K. Raghavendra Rao, Managing Director has been appointed as the Chairman and Managing Director. Mr.Deepak Vaidya who has been on the Board as a nominee of Symphony Capital Partners (Asia) Pte Ltd will continue to be on the Board as an Independent director subsequent to the sale by Symphony Capital Partners (Asia) Pte Ltd. of their shareholding in Orchid. The above has been approved by the Board of Directors of the Company at its meeting held on October 28, 2010.28 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 36832.34 lacs for quarter ending on 30-SEP-2010 against Rs. 30484.59 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 2401.49 lacs for the quarter ending on 30-SEP-2010 against Rs. (1320.17) lacs for the quarter ending on 30-SEP-2009.19 Oct · Management
Shri. Anil Thadani has resigned from the Board of the Orchid Chemicals & Pharmaceuticals Limited with effect from September 28, 2010. Subsequent to his resignation, Shri. Rajgopal Rajkumar, Alternate Director to Shri. Anil Thadani, also vacates the office of Directorship with effect from September 28, 2010.15 Oct · Board meeting
To take on record the unaudited financial results of the Company for the period from July 01, 2010 to September 30, 2010.